ISPMD 2024 poster: Pharmacodynamics of eladocagene exuparvovec and safety of the SmartFlow magnetic resonance-compatible ventricular cannula for administering eladocagene exuparvovec in paediatric participants
This poster, presented at ISPMD 2024, explores the administration of eladocagene exuparvovec using the SmartFlow magnetic resonance (MR)-compatible ventricular cannular in pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency
- Review the pathophysiology of AADC deficiency, a rare neurotransmitter-related disease
- Learn about the SmartFlow MR-compatible ventricular cannular for intraputaminal administration
- Assess the pharmacodynamics and safety of eladocagene exuparvovec using the SmartFlow MR-compatible ventricular cannular in pediatric patients with AADC deficiency
MED-US-CORP-2500008 | November 2025
This poster was developed and funded by PTC Therapeutics for ISPMD 2024.
Thank you!
Already registered?
Register now to access the content on this page
Already registered?
If not, register below
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
MED-US-CORP-2600001 | February 2026
COMING SOON
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.